-
October 10, 2008
It might be a lot of money to the average person, but $1 billion is small change on Wall Street. We look at a few ...
-
October 07, 2008
The acquisition of the cancer drug maker is not the slam-dunk that Eli Lilly might like investors to think it is.
-
October 07, 2008
Eli Lilly expands its cancer offering with the acquisition of Imclone. Can the union boost Eli Lilly's floundering ...
-
October 06, 2008
A list of five stocks trading on large volume Monday morning.
-
September 02, 2008
Bristol-Myers Squibb and Eli Lilly & Co have held up well over the past three difficult months, have good dividends ...
-
August 29, 2008
Pfizer has plenty of free cash for R&D or acquisitions, and its low forward P/E provides a solid margin of safety.
-
March 04, 2008
Duke Energy's very healthy dividend yield makes it a solid investment as a fixed-income proxy, especially during a ...
-
August 08, 2007
Make the leap with three pharmaceutical companies who require investor courage but could provide a healthy return.
-
May 17, 2007
Investors seeking big pharma exposure often confine themselves to the United States, but the best drug company just ...
-
April 20, 2007
J&J beat its Q1 consensus number with ease, so where is the stock is headed from here?
-
March 14, 2007
Generic drug manufacturers continue pose a potent threat to the established "big pharma" companies.
-
January 24, 2007
While Pfizer's current issues are cause for concern, the company's long-term plans make it worth a second look.
-
December 04, 2006
Despite its recent setbacks, PFE still remains an attractive buy -- at the right price.
-
November 16, 2006
Despite BMY's recent struggles with its Plavix sales, favorable demographics make the stock a good investment to ...
-
September 18, 2006
A look into the merger possiblities of three of the drug industry's major players.
-
August 14, 2006
Despite Merck's foibles, a cure could be on the way.
-
January 18, 2006
The bidding war for Guidant Corporation continues to heat up.
